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Background: Gefitinib, an inhibitor of the epidermal growth factor
receptor (EGFR) pathway, has single agent activity in non-small cell
lung cancer (NSCLC). Preclinical studies demonstrate significant
interactions between the EGFR and cyclooxygenase 2 (COX-2)
pathways and that simultaneous inhibition may have benefits over
EGFR inhibitors alone.
Methods: Eligibility criteria: chemotherapy-naive, stage IIIb (with
pleural effusion) or IV NSCLC, Eastern Cooperative Oncology
Group Performance Status (PS) 0–1. Patients were treated with
gefitinib 250 mg po daily plus celecoxib 400 mg po every 12 hours.
Cycles consisted of 21-day treatment and continued until unaccept-
able toxicity or progression of disease. The primary objective was to
evaluate the overall response rate; secondary objectives included
estimation of progression free survival, overall survival, and to
assess the toxicity of this regimen.
Results: From January 2004 to November 2004, 31 patients were
enrolled: male/female 13/18; median age 70 years (range, 19–93);
68% had adenocarcinoma; Eastern Cooperative Oncology Group PS
0/1 13/18; stage IIIb/IV 2/29. Two patients died of interstitial lung
disease due to treatment. There were three additional deaths during
treatment that were not considered treatment related. Two additional
patients discontinued treatment due to adverse events (elevated liver
enzymes). Select grade 3/4 toxicities included: pneumonitis (3%),
hepatic (7%), diarrhea (7%), and skin (3%). Response rate was 16%
(95% CI, 5–34%), median progression free survival and overall
survival were 3.2 (95% CI, 2.7–5.7 months) and 7.0 months (95%
CI, 3.7–14.2 months), respectively. All responders were females
with adenocarcinoma, two were remote or never smokers and three
were former smokers.
Conclusion: Gefitinib plus celecoxib in an unselected population of
chemotherapy naive patients with advanced NSCLC and a PS of
0–1 has a lower response rate and overall efficacy compared with
historical controls of combination chemotherapy.
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Lung cancer is the leading cause of cancer-related death inboth men and women in the United States, with 160,390
projected deaths in the year 2007.1 Approximately 85% of
these patients will have non-small cell lung cancer (NSCLC)
type and the majority will present with advanced disease.
Modest gains in survival time and quality of life have resulted
from the use of chemotherapy in patients with advanced
NSCLC.2–6 A multicentered trial from the United Kingdom
randomizing patients to supportive care versus platinum-
based chemotherapy demonstrated a small, but statistically
significant, survival advantage for the use of chemotherapy.6
Unfortunately, a plateau in survival times has been reached as
comparable survival results are reported with several differ-
ent regimens.7 Furthermore, although survival gains are usu-
ally modest with chemotherapy, many patients experience grade
3 or 4 toxicities, the extent of which differs based upon the
regimen used. Novel strategies and therapeutics with safer side
effect profiles are greatly needed for this patient population.
Gefitinib is an inhibitor of the epidermal growth factor
receptor (EGFR) intracellular tyrosine kinase. Inhibition of
this signal transduction cascade can affect tumor growth,
angiogenesis, and survival of lung cancer cell lines. Phase II
trials of gefitinib in previously treated patients with advanced
NSCLC reported response rates of 11.8% and18.4%, respec-
tively.8,9 Substantially more patients achieved stable disease
for at least 3 months, so that the disease control rate was
approximately 40 to 50%, comparable to what is achieved
with chemotherapy in this setting. At a dose of 250 mg daily,
gefitinib was generally well tolerated with few instances of
grade 3 or 4 toxicity.
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Cyclooxygenase-2 (COX-2) is also believed to play an
important role in the pathogenesis of some malignancies.
Investigators at Indiana University characterized the fre-
quency of COX-2 expression by immunoblot analysis in
primary lung cancers from frozen tumor tissue and matched
normal adjacent tissue.10 COX-2 protein was expressed more
frequently and at higher levels in adenocarcinomas and squa-
mous cell carcinomas of the lung when compared with the
normal adjacent tissue. Preclinical data has shown that
COX-2 inhibitors inhibit both in vitro and in vivo growth of
human cancer lines, demonstrate antiangiogenic activity, in-
creased cellular apoptosis, and decreased cellular prolifera-
tion.11–13 Furthermore, significant intracellular interactions
between the EGFR pathway and COX-2 pathway have been
reported in preclinical studies, suggesting that simultaneously
inhibiting both targets may provide enhanced benefits.14–17
Therefore, based on the desire to develop more effective and
safer regimens for patients with advanced NSCLC, this study
was designed to assess the efficacy of gefitinib, an EGFR
inhibitor, with celecoxib, a COX-2 inhibitor, in chemotherapy-
naive patients with stage IIIb or IV NSCLC.
PATIENTS AND METHODS
Patients were enrolled from participating sites of the
Hoosier Oncology Group, a community-based cooperative
group. Eligible patients met the following criteria: histologic
or cytologic evidence of NSCLC, stage IIIB disease with
pleural effusion and/or positive supraclavicular nodes or
stage IV disease, chemotherapy-naive, the presence of mea-
surable disease per the RECIST criteria, an Eastern Cooper-
ative Oncology Group Performance Status of 0 or 1 at
baseline, adequate baseline hematologic function (absolute
neutrophil count 1500/mm3, platelet count 100,000/mm3,
hemoglobin level 8 g/dl), hepatic function (total bilirubin
level 2 mg/dl, aspartate aminotransferase and alkaline
phosphatase 2.5  upper limits of normal), and renal
function (serum creatinine level 2 mg/dl or a calculated
creatinine clearance 50 ml/min). Radiotherapy was al-
lowed, provided the radiated area was not the only site of
measurable disease and was completed 21 days before
study registration. Patients with brain metastases were eligi-
ble if the brain metastases were adequately treated, asymp-
tomatic, and clinically stable for at least 2 weeks. Patients
were excluded if they had received prior anti-EGFR therapy,
had a prior malignancy, except for adequately treated basal
cell or squamous cell skin cancer, in situ cervical cancer,
Gleason grade 7 organ confined prostate cancer or other
cancers for which the patient has been disease-free for 3
years; history of severe or uncontrolled systemic disease
(e.g., unstable or uncompensated respiratory, hepatic, or renal
disease), active infections, history of neuropathic keratopa-
thy, current treatment for ocular inflammation or corneal
ulceration, or evidence of clinically active interstitial lung
disease (patients with chronic stable radiographic changes
who were asymptomatic were not excluded). Pregnant or
lactating women were excluded and women of childbearing
potential and sexually active males had to be willing to use
contraception during and for 3 months after completion of
protocol therapy. All patients gave written informed consent
and HIPAA authorization for release of protected health
information. The local institutional review boards approved
the protocol before enrollment at each site.
All patients were treated with gefitinib 250 mg po daily
plus celecoxib 400 mg po every 12 hours. The study was
stopped after we failed to meet our endpoints from stage I to
go on to stage II. Each cycle consisted of a 21-day time period
and treatment continued until disease progression or intoler-
able toxicities occurred. Physical exams and toxicity evalua-
tions were completed at baseline and before each cycle and
disease assessment was undertaken at baseline and prior to
every other cycle. Toxicities were graded using the Common
Toxicity Criteria version 3.0. Day 1 treatment of a new cycle
was administered only when the absolute neutrophil count
was 1000/L and platelets 100,000/L. Patients who re-
quired greater than a 14-day interruption in therapy due to
toxicity were taken off study. There were no dose reductions
allowed for gefitinib. Patients with grade 3 or 4 skin toxicity,
diarrhea, stomatitis and/or any other significant toxicity
thought to be related to gefitinib were treated with supportive
care and gefitinib could be held up to 14 days. Treatment was
restarted when the patient recovered to baseline or grade 2.
If patients presented with an acute worsening or new onset of
respiratory symptoms such as dyspnea, cough, and fever,
gefitinib therapy was interrupted and evaluation for intersti-
tial lung disease (ILD) was initiated. If ILD was confirmed,
gefitinib was permanently discontinued. If a patient devel-
oped any grade 3 or 4 toxicity attributable to celecoxib,
treatment with celecoxib was interrupted until symptoms
resolved to a grade 2 or less toxicity and then celecoxib was
resumed at a 50% dose reduction. Gastrointestinal bleeding
attributable to celecoxib would have required the patient be
taken off study. A maximum 14-day treatment interruption was
allowed with only one dose reduction allowed per patient.
Of note, a study amendment was made on December
21, 2004, stopping the use of celecoxib after evidence was
shown correlating the drug with increased risk of serious
cardiovascular events.18 This amendment was made during
the interval between the first and second stages while the data
was being analyzed to see if we would proceed with the second
stage. This amendment would have only affected those still on
study as no further patients were accrued for the study.
Statistical Considerations
The primary objective of this multiinstitutional phase II
study was to estimate the overall response rate of the com-
bination of gefitinib plus celecoxib in this patient population.
Secondary objectives included estimation of progression free
survival, overall survival, and to assess the toxicity of this
regimen. Patients were to be entered in two stages. If 10 of
the initial 30 patients achieved an objective response, the
study would be terminated. If 10 of the initial 30 patients
achieved an objective response, accrual would continue to a
total 50 patients. A one-sided statistical test was to be carried
out at the 10% alpha level. The null hypothesis would be
rejected if the lower bound of a one-sided 90% confidence
interval constructed around the observed response rate is
higher than the historical response rate of 30%. The hypoth-
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esis that the response rate is below 30% would be rejected in
favor of the alternative that the true response rate is higher
than 30% if at least 20 of 50 evaluable patients respond. If the
true response rate is 45% or higher, this design was expected
to provide better than 80% power to confirm that the true
response rate is no less than 30%. For progression-free
survival and overall survival, a lower 90% one-sided confi-
dence interval was constructed around the observed median
(either median time to progression or death). Therapy was to
be considered having exceeded the current therapeutic standard
at the 90% confidence level if the lower bound of this confidence
interval was higher than 4 and 10 months, respectively.
Response was assessed using the RECIST criteria, and
all responses were confirmed a minimum of 4 weeks after the
initial response was recorded. Duration of response is defined
among responders from earliest date of response to date of
progression or death, with those continuing to respond at last
data collection as censored. To be assigned a status of stable
disease, measurements on imaging could neither have had
sufficient shrinkage to qualify for partial response nor suffi-
cient criteria to show progressive disease. This had to have
been shown at least once after study entry at a minimum of 6
to 8 weeks. Survival end point is defined as time to death with
surviving patients at last data collection as censored. Progres-
sion-free survival is defined as time to death or date of
progression with surviving patients at last data collection as
censored. Follow-up time end point is date of last data
collection with censoring at death.
RESULTS
From January 2004 to November 2004, 31 eligible
patients were entered onto the study. Two patients were
simultaneously consented from separate sites on the same
day. Therefore, we elected to allow both patients to enroll.
This increased enrollment by 1 patient for the first stage of the
study. The study did not meet its predefined criteria of an
observation of at least 30% response rate to continue beyond
the first stage. Patient demographics and disease characteris-
tics are summarized in Table 1. The majority of patients were
female and former smokers; adenocarcinoma was the predomi-
nant histologic type. All but two patients had stage IV disease
with Eastern Cooperative Oncology Group performance status
of 0 for 13 patients and 1 for 18 patients. The median number of
completed cycles was 4 (range, 0–19). There were seven pa-
tients who stopped celecoxib permanently in December 2004,
when the amendment to do so took effect.
Toxicity
Toxicity data is summarized in Table 2 for all patients
(n 31). Two patients died as a result of toxicity. One female
patient, with no prior radiotherapy, developed interstitial lung
disease and died 2 to 3 weeks after initiating treatment. Of
note, she had pneumonia 4 months before entering the study.
The second patient who died due to treatment also died of
interstitial lung disease. The patient was a male who had prior
radiotherapy to the chest and back completed in September
2004 and started protocol therapy in October 2004. After 6
weeks, he had stable disease but had increasing radiation-
markings. He became dyspneic and was given oxygen and
steroids for presumed pneumonitis. His symptoms worsened
and he died in January 2005, just 2 months after starting
protocol therapy. Another patient with known prior history of
congestive heart failure developed symptoms of lethargy and
respiratory distress with signs of rhonchi and rales on phys-
ical examination. Chest radiograph confirmed volume over-
load and despite diuretic and aerosol treatments the patient
died; however, this was not considered treatment related.
There were two other patients who died while on treatment,
one from Guillain-Barre and another who died suddenly from
a presumed pulmonary embolus, not considered to be treat-
TABLE 1. Patient Demographics and Disease Characteristics
Count Percent
Sex
Female 18 58
Male 13 42
Histology
Adenocarcinoma 21 68
Squamous cell carcinoma 2 6
Other 8 26
ECOG performance
0 13 42
Status
1 18 58
Stage
IIIB 2 6
IV 29 94
Smoking history
Never smoked 5 16
Former Smoker 20 65
Current Smoker 5 16
Unknown 1 3
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Combined Grade 3 and 4 Toxicities
Toxicity Count Percent
ALT, SGPT (serum glutamic pyruvic transaminase) 2 7
Atelectasis 1 3
Cardiac 1 3
Diarrhea 2 7
Dizziness 1 3
Dyspnea 4 13
Fatigue 2 7
Hyperkalemia 1 3
Hypotension 1 3
Mucositus 1 3
Non-neutropenic infection 1 3
Pneumonitis/pulmonary infiltrates 1 3
Pulmonary/upper respiratory 3 10
Renal 1 3
Skin 1 3
Vomiting 1 3
Weight loss 1 3
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ment related. Two patients discontinued treatment before
disease progression due to elevated liver enzymes. Twelve
patients (39%) had at least one grade 3 or 4 toxicity. Three
patients (10%) had grade 3 diarrhea. There were no instances
of grade 3 or 4 rash, gastrointestinal bleeds, myocardial
infarctions, or cerebrovascular accidents.
Efficacy
All patients (n  31) were considered evaluable for
response, progression-free survival, and overall survival. Five
patients achieved a partial response (16%, 95% CI, 5–34%),
whereas an additional 14 patients (45%, 95% CI, 27–64%)
had stable disease; the remaining 12 patients (39%, 95% CI,
22–58%) had progressive disease. The overall disease control
rate (partial response plus stable disease) was 61% (95% CI,
42–78%). Median duration of response among five respond-
ers was 2.8 months (range of response, 1.5–20.5 months.)
Characteristics of the five patients with a partial response are
summarized in Table 3. As of this analysis, 9 of 31 patients
were alive. The median progression-free survival and overall
survival times were 3.2 (95% CI, 2.5–5.7 months) and 7.0
months (95% CI 3.7–14.2 months), respectively (Figure 1
and 2). The 1-year survival estimate is 38% (95% CI, 21–
55%).
DISCUSSION
To our knowledge, this is the only published phase II
study evaluating the combination of gefitinib plus celecoxib
in good performance status patients with advanced NSCLC
treated in the first line. Our reported response rate with this
combination was similar to the single agent activity of ge-
fitinib alone in a similar patient population, and thus we failed
to meet our primary goal and did not continue the study onto
its second stage.19–23 Furthermore, this regimen seems less
active than many combination chemotherapy regimens in a
similar patient population.7,24,25 In addition, despite having a
performance status of 0 or 1 at study entry, the median
survival time of only 7.0 months is substantially lower than
historical controls with chemotherapy as first line therapy
(9–10 months) for this patient population on most recent
studies. Although five patients did achieve a partial response,
including some with durable responses, it is unclear what the
contribution of celecoxib was for these patients.
Other studies have combined EGFR-tyrosine kinase
inhibitors with disappointing results. Gadgeel et al. had a
response rate of 7% when combining gefitnib with celecoxib
in patients with platinum refractory NSCLC.26 O’Byrne et al.
combined gefitinib with rofecoxib in patients with platinum-
pretreated relapsed NSCLC resulting in a 7% response rate.27
Another study combining erlotinib with celecoxib in patients
with relapsed NSCLC resulted in an 8% response rate.28
Several studies evaluating single agent gefitinib in a
chemonaive patients have been reported. Niho et al. reported
a response rate of 30% and median survival of 13.9 months
with gefitinib as first-line treatment in advanced NSCLC in an
Asian population.19 Responders on this trial were generally
female patients with adenocarcinoma, similar to observations
on other studies, including the current study.10,11 Our data
suggests that females who never smoked may be a patient
population who would be best treated with an EGFR inhibitor
upfront. Whether sequencing of therapy with an EGFR in-
hibitor as first-line therapy followed by chemotherapy second
line would affect overall outcomes compared with the reverse
order in this patient population remains unknown. Such a
question would be worthy of testing in a randomized trial.
Although four randomized trials failed to demonstrate a
survival difference when treating patients with chemotherapy
alone versus chemotherapy plus an EGFR inhibitor, subset
analyses on at least two of these trials suggested that in never
smokers a survival advantage may still be realized with
combined chemotherapy and EGFR blockade.29–32 This strat-
egy is being tested in a randomized study by the CALGB in
which patients receive erlotinib alone versus chemotherapy
plus erlotinib.
In the second-line setting, several studies have com-
bined a chemotherapy agent with a COX-2 inhibitor, suggest-
ing some subsets may benefit from the addition of a COX-2
inhibitor. For example, although Csiki et al. showed no
difference in survival by combining celecoxib with docetaxel
compared with docetaxel alone as second line therapy, their
data suggested that patients with the greatest proportional
decline in urinary PGE-M levels experienced survival pro-
longation when compared with those with no change or an
increase in PGE-M (14.8 versus 6.3 versus 5 months).33
Nugent et al. report in a phase II study of docetaxel and
celecoxib in previously treated patients with NSCLC that the
FIGURE 1. Kaplan-Meier curve for overall survival.
TABLE 3. Characteristics of Responding Patients
Sex Age Orig. Description Pks/yrr Smoking Status
F 70 Lung Adenocarcinoma Never smoked
F 56 Lung Adenocarcinoma 20 Quit 3 mo ago
but 30 yr
F 48 Lung Adenocarcinoma 20 Quit 3 mo ago
but 30 yr
F 58 Lung Adenocarcinoma 20 Quit 3 mo ago
but 30 yr
F 73 Bone Adenocarcinoma Hasn’t smoked in
30 yr
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addition of celecoxib may prolong time to disease progres-
sion.34 Gasparini et al. evaluated the combination of cele-
coxib with weekly paclitaxel and measured circulating vas-
cular endothelial growth factor and reported the subset of
patients who responded to the combination of celecoxib and
paclitaxel also showed decreased levels of serum vascular
endothelial growth factor.35
Pulmonary toxicity, in particular ILD, remains a con-
cern for a small percentage of patients treated with EGFR
inhibitors. The study by Niho et al. reported a 10% rate of
ILD in their studied Japanese population.19 Other trials sug-
gest much lower rates.9,36 In the current study, 2 of 31
patients (7%) developed ILD, both of whom died. There were
only four patients whom experienced grade 3 and 4 toxicity
of dyspnea.
Continued exploration of treating unselected patient
populations with targeted agents such as gefitinib or cele-
coxib are unlikely to significantly improve outcomes. In
addition to the potential biomarkers mentioned to determine
celecoxib sensitivity, several predictors of gefitinib efficacy
have been reported. These include the presence of mutation in
the EGFR tyronine kinase domain, increased gene copy
number of EGFR band on FISH analysis, lack of Kras
mutations, and lack of pTEN loss among others.37–39
In conclusion, this study combining gefitinib with cele-
coxib failed to demonstrate improved outcomes when com-
pared with historical controls of chemotherapy in a similar
patient population. As such, we do not recommend pursuit of
this combination in an unselected patient population. The
value of adding celecoxib to gefitinib remains in doubt,
although worthy of further pursuit if a select patient popula-
tion can be identified.
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